A randomized phase III study

Comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas

F. Imbesi, E. Marchioni, E. Benericetti, F. Zappoli, A. Galli, M. Corato, Mauro Ceroni

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: In this randomized phase III study, the effectiveness as well as the side-effects of intraarterial [i.a.] (17 patients) versus intravenous [i.v.] (16 patients) ACNU [Nimustine] administration in newly diagnosed glioblastoma, were compared. Patients and Methods: All patients underwent extensive surgical resection, and both groups were homogeneous for the other known risk factors. Thirty-three patients with glioblastoma were treated with ACNU at the dose of 80-100 mg/m2. Treatment was repeated every 5-8 weeks for a minimum of 2 and maximum of 14 cycles. Total survival time (TST) and to time to progression were chosen as outcome variables. Results and Conclusion: No significant differences in systemic and hematological toxicity between the i.a. and i.v. ACNU administration routes were detected. In both groups, tolerance of the procedure was excellent. Analysis of the main outcome measured showed no significant differences between i.a. and i.v. ACNU administration: time to progression was 6 months for i.a. ACNU and 4 months for i.v. ACNU and total survival time was 17 months for i.a. ACNU and 20 months for i.v. ACNU. In spite of ACNU dose incrementation, obtained through i.a. route administration, and subsequent higher concentration in the tumor bed, no improvement could be achieved in effectiveness.

Original languageEnglish
Pages (from-to)553-558
Number of pages6
JournalAnticancer Research
Volume26
Issue number1 B
Publication statusPublished - Jan 2006

Fingerprint

Nimustine
Glioblastoma
Intravenous Administration
Survival

Keywords

  • Glioma ACNU
  • Intraarterial
  • Intravenous

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{d875bdd7e6fc4bdaa89b9fe0ca413cc2,
title = "A randomized phase III study: Comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas",
abstract = "Background: In this randomized phase III study, the effectiveness as well as the side-effects of intraarterial [i.a.] (17 patients) versus intravenous [i.v.] (16 patients) ACNU [Nimustine] administration in newly diagnosed glioblastoma, were compared. Patients and Methods: All patients underwent extensive surgical resection, and both groups were homogeneous for the other known risk factors. Thirty-three patients with glioblastoma were treated with ACNU at the dose of 80-100 mg/m2. Treatment was repeated every 5-8 weeks for a minimum of 2 and maximum of 14 cycles. Total survival time (TST) and to time to progression were chosen as outcome variables. Results and Conclusion: No significant differences in systemic and hematological toxicity between the i.a. and i.v. ACNU administration routes were detected. In both groups, tolerance of the procedure was excellent. Analysis of the main outcome measured showed no significant differences between i.a. and i.v. ACNU administration: time to progression was 6 months for i.a. ACNU and 4 months for i.v. ACNU and total survival time was 17 months for i.a. ACNU and 20 months for i.v. ACNU. In spite of ACNU dose incrementation, obtained through i.a. route administration, and subsequent higher concentration in the tumor bed, no improvement could be achieved in effectiveness.",
keywords = "Glioma ACNU, Intraarterial, Intravenous",
author = "F. Imbesi and E. Marchioni and E. Benericetti and F. Zappoli and A. Galli and M. Corato and Mauro Ceroni",
year = "2006",
month = "1",
language = "English",
volume = "26",
pages = "553--558",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - A randomized phase III study

T2 - Comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas

AU - Imbesi, F.

AU - Marchioni, E.

AU - Benericetti, E.

AU - Zappoli, F.

AU - Galli, A.

AU - Corato, M.

AU - Ceroni, Mauro

PY - 2006/1

Y1 - 2006/1

N2 - Background: In this randomized phase III study, the effectiveness as well as the side-effects of intraarterial [i.a.] (17 patients) versus intravenous [i.v.] (16 patients) ACNU [Nimustine] administration in newly diagnosed glioblastoma, were compared. Patients and Methods: All patients underwent extensive surgical resection, and both groups were homogeneous for the other known risk factors. Thirty-three patients with glioblastoma were treated with ACNU at the dose of 80-100 mg/m2. Treatment was repeated every 5-8 weeks for a minimum of 2 and maximum of 14 cycles. Total survival time (TST) and to time to progression were chosen as outcome variables. Results and Conclusion: No significant differences in systemic and hematological toxicity between the i.a. and i.v. ACNU administration routes were detected. In both groups, tolerance of the procedure was excellent. Analysis of the main outcome measured showed no significant differences between i.a. and i.v. ACNU administration: time to progression was 6 months for i.a. ACNU and 4 months for i.v. ACNU and total survival time was 17 months for i.a. ACNU and 20 months for i.v. ACNU. In spite of ACNU dose incrementation, obtained through i.a. route administration, and subsequent higher concentration in the tumor bed, no improvement could be achieved in effectiveness.

AB - Background: In this randomized phase III study, the effectiveness as well as the side-effects of intraarterial [i.a.] (17 patients) versus intravenous [i.v.] (16 patients) ACNU [Nimustine] administration in newly diagnosed glioblastoma, were compared. Patients and Methods: All patients underwent extensive surgical resection, and both groups were homogeneous for the other known risk factors. Thirty-three patients with glioblastoma were treated with ACNU at the dose of 80-100 mg/m2. Treatment was repeated every 5-8 weeks for a minimum of 2 and maximum of 14 cycles. Total survival time (TST) and to time to progression were chosen as outcome variables. Results and Conclusion: No significant differences in systemic and hematological toxicity between the i.a. and i.v. ACNU administration routes were detected. In both groups, tolerance of the procedure was excellent. Analysis of the main outcome measured showed no significant differences between i.a. and i.v. ACNU administration: time to progression was 6 months for i.a. ACNU and 4 months for i.v. ACNU and total survival time was 17 months for i.a. ACNU and 20 months for i.v. ACNU. In spite of ACNU dose incrementation, obtained through i.a. route administration, and subsequent higher concentration in the tumor bed, no improvement could be achieved in effectiveness.

KW - Glioma ACNU

KW - Intraarterial

KW - Intravenous

UR - http://www.scopus.com/inward/record.url?scp=32144436309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144436309&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 553

EP - 558

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -